Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ferozsons LaboratoriesKAR:FEROZ -2.38%70 Quick Ratio is 0.76 as of Mar. 2026, which is 52% below its 10-year median of 1.57. GuruFocus rates KAR:FEROZ with a GF Score™ of 70/100 and a GF Value™ of ₨419.78 (Fairly Valued). The stock has 4 warning signs investors should review. Among 999 Drug Manufacturers companies, Ferozsons Laboratories ranks worse than 77.98% on this metric.
Ferozsons Laboratories has a quick ratio of 0.76. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Ferozsons Laboratories's Quick Ratio or its related term are showing as below:
KAR:FEROZ'
s Quick Ratio Range Over the Past 10 Years
Min: 0.61 Med: 1.57 Max: 2.62
Current: 0.76
During the past 11 years, Ferozsons Laboratories's highest Quick Ratio was 2.62. The lowest was 0.61. And the median was 1.57.
KAR:FEROZ's Quick Ratio is ranked worse than 77.98% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs KAR:FEROZ: 0.76
Ferozsons Laboratories (KAR:FEROZ) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Ferozsons Laboratories Quick Ratio Related Terms
Ferozsons Laboratories Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:FEROZ vs ZTS, UTHR, VTRS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ferozsons Laboratories Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Ferozsons Laboratories's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Ferozsons Laboratories's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ferozsons Laboratories (KAR:FEROZ) has a Quick Ratio of 0.76 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ferozsons Laboratories and its competitors. This is 52% below median its historical median of 1.57. Over the past decade, Ferozsons Laboratories' Quick Ratio has ranged from 0.61 to 2.62. According to the industry distribution chart, Ferozsons Laboratories ranks #779 out of 999 companies in the Drug Manufacturers industry, placing it in the top 78%.
Is Ferozsons Laboratories' Quick Ratio too high?
Ferozsons Laboratories' current Quick Ratio of 0.76 is 52% below median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 2.62. The Drug Manufacturers industry median Quick Ratio is 1.45. Ferozsons Laboratories' value of 0.76 is 47.6% below this industry median. Based on the distribution chart, Ferozsons Laboratories ranks #779 out of 999 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ferozsons Laboratories has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ferozsons Laboratories' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ferozsons Laboratories ranks #779 out of 999 companies for Quick Ratio. This places Ferozsons Laboratories in the lower half of its industry. The industry median Quick Ratio is 1.45. Ferozsons Laboratories' value of 0.76 is 47.6% below this benchmark. Historically, Ferozsons Laboratories' own Quick Ratio has ranged from 0.61 to 2.62 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 1.45, Ferozsons Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ferozsons Laboratories's current Quick Ratio of 0.76 is 47.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ferozsons Laboratories and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ferozsons Laboratories's current Quick Ratio is 0.76, which is 52% below median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ferozsons Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ferozsons Laboratories (KAR:FEROZ) is currently considered Fairly Valued. The stock's GF Value™ is ₨419.78, compared to a current price of ₨391.89 — trading 6.6% below its estimated fair value. The current Quick Ratio is 0.76, which is 52% below median its 10-year median of 1.57 and 47.6% below the Drug Manufacturers industry median of 1.45. Ferozsons Laboratories' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Ferozsons Laboratories (KAR:FEROZ), the current Quick Ratio is 0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ferozsons Laboratories (KAR:FEROZ) Overvalued in 2026?
Based on GuruFocus' analysis, Ferozsons Laboratories stock appears to be undervalued.
The current stock price of ₨391.89 is trading 6.6% below its estimated GF Value™ of ₨419.78.
GuruFocus considers Ferozsons Laboratories to be Fairly Valued.
Key valuation signals for KAR:FEROZ:
Quick Ratio: 0.76 (52% below median its 10-year median of 1.57)
GF Value™: ₨419.78 vs. price of ₨391.89 (6.6% below fair value)
Industry Position: 47.6% below the Drug Manufacturers median (#779 of 999)
No single metric tells the full story. See the KAR:FEROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and diabetes. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. The company operates in three segments namely Ferozsons, BF Biosciences, and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.
70GF Score
Get the complete analysis for KAR:FEROZ
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:FEROZ has been successfully added to your 
